2.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
3.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
4.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
5.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
6.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
7.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
8.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
9.Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru NAKAMURA ; Masahito NAKANO ; Tsubasa TSUTSUMI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):705-708
10.Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa TSUTSUMI ; Dan NAKANO ; Machiko KAWAGUCHI ; Hirokazu TAKAHASHI ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(2):266-268
Result Analysis
Print
Save
E-mail